Skip to content
DraconiticResearch
Search Sources API
186,631 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BYBlood Cancer Journal

Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy

  • Yu-Yuan Zeng1
  • Guan-Hua Hu2
  • Ying-Xi Zuo2
  • Pan Suo2
  • Lu Bai2
  • Feng Zhang2
  • Hui-Fang Wang2
  • Ying-Jun Chang2
  • Meng Lv2
  • Xiao-Hui Zhang2
  • Yu Wang2
  • Lan-Ping Xu2
3 more authors
  • Xiao-Jun Huang2
  • Lin Wang1
  • Yi-Fei Cheng2
  1. 1Department of Child Health Care, Capital Center for Children’s Health, Capital Medical University
  2. 2Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences
Read full textPDFDOICite

Related

  1. Clinical outcomes and prognostic factors after first- and second-line immunotherapy in a cohort of 57 patients with refractory autoimmune encephalitis
    Jiao He, Haozhe Lu
    Frontiers in immunologyPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  2. Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
    Pragya Rai, Yu-Han Kao, Xiaohan Hu +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  3. Kinetics of early immune reconstitution and its exploratory association with post-transplant outcomes in patients undergoing haploidentical HCT with post-transplant cyclophosphamide-based GvHD prophylaxis
    Nayanthara K. Bijukumar, Aswin Anand Pai, Rachel Mariam Renji +15
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  4. PO110 | CLINICAL OUTCOMES AND SURVIVAL OF UNUSUAL SITE VENOUS THROMBOSIS IN PATIENTS WITH AND WITHOUT MYELOPROLIFERATIVE NEOPLASMS: A RETROSPECTIVE SINGLE-CENTER STUDY
    Irene Bertozzi
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  5. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{zeng2026immune,
  title = {{Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy}},
  author = {Yu-Yuan Zeng and Guan-Hua Hu and Ying-Xi Zuo and Pan Suo and Lu Bai and Feng Zhang and Hui-Fang Wang and Ying-Jun Chang and Meng Lv and Xiao-Hui Zhang and Yu Wang and Lan-Ping Xu and Xiao-Jun Huang and Lin Wang and Yi-Fei Cheng},
  journal = {Blood Cancer Journal},
  year = {2026},
  month = oct,
  doi = {10.1038/s41408-026-01638-0},
  url = {https://doi.org/10.1038/s41408-026-01638-0},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy
AU  - Yu-Yuan Zeng
AU  - Guan-Hua Hu
AU  - Ying-Xi Zuo
AU  - Pan Suo
AU  - Lu Bai
AU  - Feng Zhang
AU  - Hui-Fang Wang
AU  - Ying-Jun Chang
AU  - Meng Lv
AU  - Xiao-Hui Zhang
AU  - Yu Wang
AU  - Lan-Ping Xu
AU  - Xiao-Jun Huang
AU  - Lin Wang
AU  - Yi-Fei Cheng
PY  - 2026
DA  - 2026/10/25
JO  - Blood Cancer Journal
DO  - 10.1038/s41408-026-01638-0
UR  - https://doi.org/10.1038/s41408-026-01638-0
SN  - 2044-5385
ER  -